Cantor Fitzgerald, L. P. Neurocrine Biosciences Inc Transaction History

Cantor Fitzgerald, L. P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $10,743 - $12,584	-120 Reduced 0.13%	95,334 $8.99 Million
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $437,705 - $572,166	-4,651 Reduced 4.65%	95,454 $9.66 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $728,364 - $867,184	6,825 Added 7.32%	100,105 $12 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $8.58 Million - $10.1 Million	93,280 New	93,280 $9.91 Million

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Cantor Fitzgerald, L. P., based on Form 13F filings with the SEC.

Stay updated on Cantor Fitzgerald, L. P. with notifications on news.